Healthcare

Actinogen Medical Ltd (ASX:ACW) gained 3.66% to AUD 0.043, adding to a 57.41% one-year rise in the supplied market data as the company approaches a major clinical milestone. Actinogen is developing Xanamem, an oral therapy designed to reduce elevated cortisol in the brain, and …

BZDS1901 is the China version of EW-001, AdAlta's lead CAR-T cell therapy, containing the same engineered features. Treatment will be provided at Ruijin Hospital, Hainan, a Grade A tertiary hospital affiliated with Shanghai Jiao Tong University School of Medicine, following an independent assessment of …

Under the agreement, Vitrafy will install one Guardion cryopreservation freezing unit alongside its LifeChain software platform at Charter Medical's Innovation Hub, where the technology will support cryopreservation and freeze-curve optimisation studies for Charter Medical's cell and gene therapy customers. The Guardion unit is designed …

Percheron Therapeutics Limited (ASX:PER) has secured AUD 2.3mn in new institutional funding as its HMBD-002 program moves towards another clinical development stage. The capital raising combines new shares and free-attaching options, with proceeds directed to the planned trial and working capital.

Trajan Group Holdings Limited is a global analytical science and device company, designing andManufacturingcomponents, consumables and equipment used in scientific analysis and testing across sectors including environmental testing, food safety, pharmaceuticals and diagnostics. The company operates across segments including Components and Consumables, Disruptive Technologies …

Mayfield Childcare (ASX: MFD) enters the second half of FY26 with a mixed operating picture. Revenue declined as average occupancy softened, but tighter roster management helped keep the underlying centre EBITDAMarginbroadly stable. At the same time, liquidity has become an important part of the …

Invex Therapeutics (ASX: IXC) enters the new financial year with its development story centred on one drug and several neurological possibilities. Exenatide, an already approved medicine, is being investigated for conditions involving raised intracranial pressure as well as Alzheimer’s Disease. FY26 brought fresh preclinical …